68 related articles for article (PubMed ID: 20830227)
1. Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Hong J; Kyung SY; Lee SP; Park JW; Jung SH; Lee JI; Park SH; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
Korean J Intern Med; 2010 Sep; 25(3):294-300. PubMed ID: 20830227
[TBL] [Abstract][Full Text] [Related]
2. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Guirgis HM
J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Wong MK; Lo AI; Lam B; Lam WK; Ip MS; Ho JC
Cancer Chemother Pharmacol; 2010 May; 65(6):1023-8. PubMed ID: 19680652
[TBL] [Abstract][Full Text] [Related]
4. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Norden AD; Raizer JJ; Abrey LE; Lamborn KR; Lassman AB; Chang SM; Yung WK; Gilbert MR; Fine HA; Mehta M; Deangelis LM; Cloughesy TF; Robins HI; Aldape K; Dancey J; Prados MD; Lieberman F; Wen PY
J Neurooncol; 2010 Jan; 96(2):211-7. PubMed ID: 19562255
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib-induced Myositis: A Novel Case Report.
Sakamoto T; Saito Y; Takekuma Y; Kikuchi E; Sugawara M
Yakugaku Zasshi; 2023; 143(7):617-620. PubMed ID: 37394456
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Baseline Vitamin D Level in Patients Receiving Gefitinib-Directed Therapy for EGFR-Mutant Non-Small-Cell Lung Cancer.
Noronha V; Kolkur M; ArunKumar R; Adak S; Patil V; Menon N; Shah M; Prabhash K
Clin Med Insights Oncol; 2024; 18():11795549241254460. PubMed ID: 38827521
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Evaluation of Drug-Drug Interactions With Erlotinib and Gefitinib Use in the Military Health System.
Luong TT; Powers CN; Reinhardt BJ; McAnulty MJ; Weina PJ; Shou KJ; Ambar CB
Fed Pract; 2023 Aug; 40(Suppl 3):S24-S34. PubMed ID: 38021095
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapies for non-small cell lung cancer.
Blais N; Kassouf E
Front Oncol; 2014; 4():213. PubMed ID: 25191641
[TBL] [Abstract][Full Text] [Related]
9. NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer.
Liu M; Deng S; Xiao T; Gao J
Transl Cancer Res; 2020 Jul; 9(7):4373-4382. PubMed ID: 35117803
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
BMC Cancer; 2018 Aug; 18(1):780. PubMed ID: 30068310
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
Medicine (Baltimore); 2018 Apr; 97(16):e0460. PubMed ID: 29668619
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.
Liu Y; Zhang Y; Feng G; Niu Q; Xu S; Yan Y; Li S; Jing M
Exp Ther Med; 2017 Nov; 14(5):4017-4032. PubMed ID: 29104622
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic invasion is a significant indicator of poor patient prognosis in lung squamous cell carcinoma.
Masuda R; Kijima H; Nito M; Wada A; Matsuzaki T; Ikoma Y; Nakazato K; Masuda D; Tanaka M; Kobayashi H; Inokuchi S; Iwazaki M
Mol Med Rep; 2017 Apr; 15(4):2067-2073. PubMed ID: 28260029
[TBL] [Abstract][Full Text] [Related]
14. Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients.
Zhao Y; Shen H; Qiu C; Zhang T; Hu P; Qu X; Liu Q; Du J
Medicine (Baltimore); 2015 Oct; 94(43):e1634. PubMed ID: 26512557
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma.
Masuda D; Masuda R; Matsuzaki T; Imamura N; Aruga N; Tanaka M; Inokuchi S; Kijima H; Iwazaki M
Mol Med Rep; 2015 Nov; 12(5):7303-9. PubMed ID: 26459875
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.
Domvri K; Zarogoulidis P; Darwiche K; Browning RF; Li Q; Turner JF; Kioumis I; Spyratos D; Porpodis K; Papaiwannou A; Tsiouda T; Freitag L; Zarogoulidis K
J Cancer; 2013 Nov; 4(9):736-54. PubMed ID: 24312144
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review.
Jazieh AR; Al Sudairy R; Abu-Shraie N; Al Suwairi W; Ferwana M; Murad MH
Ann Thorac Med; 2013 Oct; 8(4):204-8. PubMed ID: 24250733
[TBL] [Abstract][Full Text] [Related]
18. [A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].
Dai H; Xu L; Xia C; Chen W
Zhongguo Fei Ai Za Zhi; 2013 Aug; 16(8):405-10. PubMed ID: 23945243
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE).
Lee KH; Lee KY; Jeon YJ; Jung MH; Son C; Lee MK; Ryu JS; Yang SH; Lee JC; Kim YC; Kim SY
Tuberc Respir Dis (Seoul); 2012 Dec; 73(6):303-11. PubMed ID: 23319992
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
